Pircher A - Search Results

1

Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients.

Pircher A, Ploner F, Popper H, Hilbe W. Pircher A, et al. Lung Cancer. 2010 Sep;69(3):265-71. doi: 10.1016/j.lungcan.2010.01.017. Epub 2010 Feb 18. Lung Cancer. 2010. PMID: 20167388 Review.

2

Increased numbers of endothelial progenitor cells in peripheral blood and tumor specimens in non-small cell lung cancer: a methodological challenge and an ongoing debate on the clinical relevance.

Pircher A, Kähler CM, Skvortsov S, Dlaska M, Kawaguchi G, Schmid T, Gunsilius E, Hilbe W. Pircher A, et al. Oncol Rep. 2008 Feb;19(2):345-52. Oncol Rep. 2008. PMID: 18202780

3

Cancer stem cells: characteristics and their potential role for new therapeutic strategies.

Bohl SR, Pircher A, Hilbe W. Bohl SR, et al. Among authors: pircher a. Onkologie. 2011;34(5):269-74. doi: 10.1159/000327815. Epub 2011 Apr 26. Onkologie. 2011. PMID: 21577035 Review.

4

Basic clinical parameters predict gefitinib efficacy in non-small cell lung cancer.

Pircher A, Ulsperger E, Hack R, Jamnig H, Pall G, Zelger B, Sterlacci W, Hilbe W, Fiegl M. Pircher A, et al. Anticancer Res. 2011 Sep;31(9):2949-55. Anticancer Res. 2011. PMID: 21868543

5

Biomarkers in tumor angiogenesis and anti-angiogenic therapy.

Pircher A, Hilbe W, Heidegger I, Drevs J, Tichelli A, Medinger M. Pircher A, et al. Int J Mol Sci. 2011;12(10):7077-99. doi: 10.3390/ijms12107077. Epub 2011 Oct 21. Int J Mol Sci. 2011. PMID: 22072937 Free PMC article. Review.

6

Endothelial progenitor cells: current issues on characterization and challenging clinical applications.

Resch T, Pircher A, Kähler CM, Pratschke J, Hilbe W. Resch T, et al. Among authors: pircher a. Stem Cell Rev Rep. 2012 Sep;8(3):926-39. doi: 10.1007/s12015-011-9332-9. Stem Cell Rev Rep. 2012. PMID: 22095429 Review.

7

Favorable prognosis of operable non-small cell lung cancer (NSCLC) patients harboring an increased expression of tumor endothelial markers (TEMs).

Pircher A, Fiegl M, Untergasser G, Heidegger I, Medinger M, Kern J, Hilbe W. Pircher A, et al. Lung Cancer. 2013 Aug;81(2):252-8. doi: 10.1016/j.lungcan.2013.04.014. Epub 2013 May 10. Lung Cancer. 2013. PMID: 23664449

8

Docetaxel in the treatment of non-small cell lung cancer (NSCLC) -- an observational study focusing on symptom improvement.

Pircher A, Wasle IK, Mian M, Gamerith G, Ulsperger E, Studnicka M, Mohn-Staudner A, Hilbe W, Fiegl M. Pircher A, et al. Anticancer Res. 2013 Sep;33(9):3831-6. Anticancer Res. 2013. PMID: 24023316

9

New antiangiogenic strategies beyond inhibition of vascular endothelial growth factor with special focus on axon guidance molecules.

Pircher A, Wellbrock J, Fiedler W, Heidegger I, Gunsilius E, Hilbe W. Pircher A, et al. Oncology. 2014;86(1):46-52. doi: 10.1159/000356871. Epub 2014 Jan 3. Oncology. 2014. PMID: 24401553 Review.

10

Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.

Pircher A, Manzl C, Fiegl M, Popper H, Pirker R, Hilbe W. Pircher A, et al. Lung Cancer. 2014 Mar;83(3):408-10. doi: 10.1016/j.lungcan.2013.12.007. Epub 2013 Dec 25. Lung Cancer. 2014. PMID: 24412619

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

146 results

Search Page

Filters